Amount of qualified sufferers: CDEC reviewed the uncertainty in the quantity of sufferers with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be labeled as obtaining gentle or average sickness could possibly have a significant b